China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials
This article was originally published in PharmAsia News
SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.
You may also be interested in...
PERTH, Australia - Columbia, Md.-based biotech firm Celsion signed a licensing agreement with Japan's Yakult Honsha covering Celsion's liposomal platform drug, ThermoDox, a heat-sensitive formulation of doxorubicin to treat liver cancer
Company’s proprietary heat-sensitive liposome could provide drug delivery for several cancer types, CEO Tardugno tells “The Pink Sheet” DAILY.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).